Emerald Advisers, LLC Sage Therapeutics, Inc. Transaction History

Emerald Advisers, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 30, 2020	SELL	$26.15 - $77.24 $3,661 - $10,813	-140 Closed	0 $0
Q4 2019 Jan 29, 2020	BUY	$60.18 - $154.77 $8,425 - $21,667	140 New	140 $10,000
Q2 2019 Jul 31, 2019	SELL	$157.85 - $183.09 $202,048 - $234,355	-1,280 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$89.33 - $163.65 $235,027 - $430,563	-2,631 Reduced 67.27%	1,280 $204,000
Q4 2018 Jan 30, 2019	SELL	$81.94 - $139.71 $47,033 - $80,193	-574 Reduced 12.8%	3,911 $375,000
Q3 2018 Oct 31, 2018	SELL	$138.11 - $169.04 $16,158 - $19,777	-117 Reduced 2.54%	4,485 $634,000
Q2 2018 Jul 31, 2018	SELL	$140.36 - $175.76 $20.8 Million - $26.1 Million	-148,311 Reduced 96.99%	4,602 $720,000
Q1 2018 Apr 26, 2018	SELL	$152.15 - $192.33 $2.41 Million - $3.05 Million	-15,872 Reduced 9.4%	152,913 $24.6 Million
Q4 2017 Feb 05, 2018	BUY	$60.72 - $167.34 $5.65 Million - $15.6 Million	93,106 Added 123.03%	168,785 $27.8 Million
Q3 2017 Oct 30, 2017	BUY	$61.4 - $88.52 $4.65 Million - $6.7 Million	75,679	75,679 $4.72 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.